Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

X experienced improvements in disease activity as measured by DAS28. Seventy-six percent of patients in the combined golimumab group were classified as DAS28 (CRP) responders, and 38 percent achieved DAS 28 remission, compared with 61 percent and 28 percent of patients receiving placebo and MTX, respectively (p<0.001 for responders and p=0.031 for remission).

"We are encouraged by the findings of both of these Phase 3 studies," said Robert J. Spiegel, M.D., chief medical officer, Schering-Plough Research Institute. "Golimumab holds great promise as an anti-TNF therapy for patients who may benefit from monthly subcutaneous injections for RA and related rheumatic diseases."

In March 2008, Centocor Inc. and Schering-Plough Corporation (NYSE: SGP) announced that a Marketing Authorization Application (MAA) had been submitted to the European Medicines Agency requesting the approval of golimumab as a monthly subcutaneous treatment for adults with RA, psoriatic arthritis and ankylosing spondylitis. The initial submission and Phase 3 development programs are unprecedented among anti-TNF-alpha therapies, as they mark the first time that an MAA has been proposed for review inclusive of three unique disease states. Golimumab, Centocor's and Schering-Plough's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy.

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite MTX therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus MTX, golimumab 100 mg plus placebo or placebo plus MTX at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Golimum
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
(Date:9/18/2014)... 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... of the underwriters, option to purchase 675,000 additional ... company,s previously announced public offering of 4,500,000 shares ... being offered by Aratana Therapeutics.  With the exercise ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/19/2014)... Columbus, OH (PRWEB) September 20, 2014 ... Philadelphia Court of Common Pleas where a meeting took ... Risperdal side-effects complaints pending in the court’s mass ... scheduled to meet this past week at the Complex ... complaints are consolidated for pretrial proceedings. The Risperdal lawsuits ...
(Date:9/19/2014)... BearCom, a nationwide provider of wireless ... role played by instant, one-to-one and one-to-many communications ... , “In healthcare, speed of information flow ... emergency situations, can save precious seconds that can ... Hugh Johnston, Product & Purchasing Manager at BearCom. ...
(Date:9/19/2014)... working with The Melanoma Genetics Consortium, GenoMEL, an international ... Journal of the National Cancer Institute that ... "For the first time, we have established that the ... part in the risk of developing melanoma," said lead ... Medicine at the University of Leeds (UK). , ...
(Date:9/19/2014)... News) -- Your brain structure could help predict how willing ... Researchers at Yale University found those with greater volume ... cortex may be more likely to engage in risky behavior ... The study, funded by the U.S. National Institute on Aging, ... in the Northeast. The researchers sought to determine how brain ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:Melanoma risk found to have genetic determinant 2Health News:Brain Structure Might Help Predict Risky Behavior 2
... bundles, scientists say , , WEDNESDAY, April 15 (HealthDay News) ... in certain neural pathways of the brain to the ... finding could lead to a better understanding of the ... and coordination that characterizes this difficult-to-diagnose disorder -- also ...
... MD, April 14, 2009 -- Sleep is such an essential ... of our lives doing it -- some more successfully than ... United States and are a major cause of disease and ... risk of heart attack, stroke, hypertension, obesity, depression, and accidents. ...
... with 100% of Updated Interoperability RequirementsTAMPA, Fla., April ... provider of electronic health records, today announced that ... has approved Sage,s product, Sage Intergy EHR, ... EHR , additionally certified for Child ...
... Harvard Business School recently completed a case study ... a private nonprofit organization that helps children and families ... a national leader in the field of children,s behavioral ... Allen Grossman, Catherine Ross of the HBS Global Research ...
... AIDS for years after initial infection by HIV have ... One component of this remarkable resistance comes from an ... genes that help the immune system recognize and fight ... the Emory Vaccine Center studying HIV-infected people with particularly ...
... minimally invasive surgical approach to treat stomach cancer has ... a preferable treatment for some patients. , A new ... (MSKCC) compares traditional "open" surgery to remove the stomach ... which the surgeon removes the stomach while guided by ...
Cached Medicine News:Health News:Brain Scans Reveal Secrets of 'Writer's Cramp' 2Health News:New way to analyze sleep disorders 2Health News:New way to analyze sleep disorders 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 2Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 3Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 4Health News:HIV handicaps itself to escape immune system pressure 2Health News:New minimally invasive surgery option for patients with stomach cancer 2
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... is a supportive .035" guide wire compatible stent system ... lengths of 18 mm, 28 mm, 38 mm and ... in 12 and 16 mm lengths. The 4.0 ... Two "diameter specific" OMNILINK® stents were developed - one ...
... particular challenge in transseptal left heart catheterization ... be exchanged for a sheath with an ... position. Traditionally, such an exchange has required ... patient. Biosense Webster has overcome this problem ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Medicine Products: